Abstract
The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).
Original language | English (US) |
---|---|
Article number | e02198 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 64 |
Issue number | 3 |
DOIs | |
State | Published - 2020 |
Keywords
- Candida auris
- Caspofungin
- Fluconazole
- In vitro susceptibility
- Invasive candidiasis
- Murine model
- T-2307
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology